Inscription Capital’s Edwards Lifesciences EW Stock Holding History

Inscription Capital’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.73M	Buy	30,214 +756	+3%	+$63.3K	0.24%	76
2026 Q1	$2.36M	Buy	29,458 +586	+2%	+$48.3K	0.25%	70
2025 Q4	$2.46M	Hold	28,872	–	–	0.25%	61
2025 Q3	$2.25M	Buy	28,872 +2,568	+10%	+$201K	0.24%	62
2025 Q2	$2.06M	Buy	26,304 +2,304	+10%	+$172K	0.3%	58
2025 Q1	$2.29M	Buy	+24,000	New	+$1.72M	0.38%	54
2024 Q3	$1.58M	Buy	24,017 +17	+0.1%	+$1.24K	0.24%	73
2024 Q2	$2.22M	Hold	24,000	–	–	0.36%	54
2024 Q1	$2.29M	Buy	+24,000	New	+$2.02M	0.38%	54
2021 Q3	–	Sell	-1,986	Closed	-$206K	–	266
2021 Q2	$206K	Buy	+1,986	New	+$187K	0.02%	305
2019 Q2	–	Sell	-24,000	Closed	-$1.53M	–	146
2019 Q1	$1.53M	Hold	24,000	–	–	0.81%	27
2018 Q4	$1.23M	Buy	+24,000	New	+$1.21M	0.68%	29

Other funds holding EW

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Inscription Capital's EW Position: Q2 2026 in Review

Inscription Capital increased its Edwards Lifesciences (EW) stake by 2.6% in Q2 2026, buying an estimated $63.3K and bringing the position to 30,214 shares worth $2.73M. The position accounts for 0.24% of the portfolio, ranked #76.

Inscription Capital first reported a position in EW in Q4 2018 and has held it in 12 quarters since. 1,327 funds tracked by Wall St. Rank hold EW as of Q2 2026.

Inscription Capital held 30,214 shares of Edwards Lifesciences worth $2.73M as of Q2 2026.
Inscription Capital bought 756 Edwards Lifesciences shares in Q2 2026, an estimated $63.3K.
Edwards Lifesciences made up 0.24% of Inscription Capital's portfolio in Q2 2026, its #76 holding.
Inscription Capital first reported a position in Edwards Lifesciences in Q4 2018 and has held it in 12 quarters since.
1,327 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Inscription Capital's 13F filing for Q2 2026, filed 13 Aug 2026.